AB Science jumps ahead into late-stage melanoma test; Apricus raises $9M;

 @FierceBiotech: Cancer researchers testing radical change in drug trials. Article | Follow @FierceBiotech

 @JohnCFierce: Langer starts biotech companies more often than I buy boots. And I have a closet full. |  Follow @JohnCFierce

> AB Science has won regulatory approval to jump right into late-stage testing of its melanoma therapy, skirting the routine need for a mid-stage study. Story

> San Diego-based Apricus Biosciences says that it raised more than $9.3 million from an offering. Story

> Akebia Therapeutics says it successfully completed a Phase 2a study for AKB-6548 in stage 3 and 4 chronic kidney disease patients. Akebia release

> Accera has named Thomas Werner as president and CEO. Accera release

> Stemedica International, a subsidiary of Stemedica Cell Technologies, has inked an agreement to form a joint venture with AnC Bio, a global manufacturer of stem cell-based products. Stemedica release

And Finally... With a keen eye to the commercial potential for a new stem cell breakthrough, Derrick Rossi joined with MIT's prolific Robert Langer and Harvard Medical School's Kenneth Chien to form ModeRNA Therapeutics with backing from Flagship Ventures. Story

Suggested Articles

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.

The trial linked RG6346 to reductions in hepatitis B surface antigen that suggest the RNAi therapy can hold its own against drugs from J&J and Vir.